HealthCore and Novo Nordisk to collaborate on long-term pragmatic clinical trial of Ozempic in Type 2 diabetic patients
HealthCore Inc. (DE, USA) and Nordisk Inc. (Bagsværd, Denmark) have plans for a randomized pragmatic clinical trial of Ozempic (semaglutide) for Type 2 diabetic patients to analyze its long-term effectiveness and real-world benefits.
Please sign in or register for FREE
Sign in to The Evidence Base
Did you know?
Your The Evidence Base™ account also gives you access to communities on regenerative medicine, real-world evidence and drug discovery. Find out more>>